The DOI matches its Crossref record; 76 of the 79 references it cites were found in a registry or an index.
Pharmacist interventions in the management of type 2 diabetes mellitus: a systematic review of randomized controlled trials.
Open accessAbstract
BACKGROUND: Diabetes mellitus is a major health problem that is growing rapidly worldwide. A collaborative and integrated team approach in which pharmacists can play a pivotal role should be sought when managing patients with diabetes. OBJECTIVE: To identify and summarize the main outcomes of pharmacist interventions in the management of type 2 diabetes. METHODS: PubMed, Cochrane Central Register of Controlled Trials, and Web of Science were searched for randomized controlled trials evaluating the effectiveness of any pharmacist intervention directed at patients with type 2 diabetes in comparison with usual care. Outcome measures of interest included glycosylated hemoglobin (Alc), blood glucose, blood pressure, lipid profile, body mass index (BMI), 10-year coronary heart disease (CHD) risk, medication adherence, health-related quality of life (HRQoL), and economic outcomes. The risk of bias in included studies was assessed using the Cochrane risk of bias tool. RESULTS: Thirty-six studies were included in this systematic review, involving 5,761 participants. The studies evaluated the effects of several pharmacist interventions carried out in various countries and in different health care facilities, such as community pharmacies, primary care clinics, and hospitals. The number of studies reporting each outcome of interest varied. Alc was evaluated in 26 studies, of which 24 reported a greater reduction in this outcome in the intervention group compared with the control group, with the difference in change between groups ranging from -0.18% to -2.1%. Eighteen studies assessed change in systolic blood pressure, of which 17 studies reported a greater improvement in this outcome in the intervention group, with the difference in change between groups varying between -3.3 mmHg and -23.05 mmHg. For diastolic blood pressure, a greater effect was also observed in the intervention group in 14 out of 15 studies, with the difference in change between groups varying between -0.21 mmHg and -9.1 mmHg. Thirteen studies described total cholesterol as an outcome measure, of which 10 reported a greater improvement in this outcome in the intervention group, with the difference in change between groups ranging from +18.95 mg dL(-1) to -32.48 mg dL(-1). With regard to low-density lipoprotein cholesterol, a greater reduction in this parameter in the intervention group was documented in 12 out of 15 studies, with the difference in change between groups varying between +7.35 mg dL(-1) and -30 mg dL(-1). Similarly, favorable data were reported on high-density lipoprotein cholesterol in the intervention group in 9 out of 12 studies that assessed this outcome, with the difference in change between groups ranging from -5.8 mg dL(-1) to +11 mg dL(-1). Data on triglycerides were also reported in 12 studies, of which 9 reported a greater reduction in triglycerides levels in the intervention group, with the difference in change between groups varying between +12 mg dL(-1) and -62 mg dL(-1). Overall, a beneficial effect on BMI was also described in the intervention group in 12 out of 14 studies. Of note, in all 6 studies that estimated the 10-year CHD risk among study patients, a greater improvement in the intervention group versus the control group was found. In addition, pharmacist interventions also had a positive impact on medication adherence and HRQoL in most studies that ascertained these outcomes. Finally, although only 3 studies conducted a cost-effectiveness analysis, pharmacist interventions proved to be cost-effective. CONCLUSIONS: The findings from this review clearly support the involvement of pharmacists as members of health care teams in the management of patients with type 2 diabetes. DISCLOSURES: This systematic review was not funded. The authors declare that they have no conflicts of interest. Concept and study design were created by Pousinho, Morgado, and Alves. Pousinho took the lead in data collection, along with Alves, and data interpretation was performed by Pousinho, Falcão, and Alves. The manuscript was primarily written by Pousinho, along with Alves, and revised by Alves, Morgado, and Falcão.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“our study findings on real practice settings follow similar trends to those reported in randomized controlled trials.”
From Using Dispensing Data to Evaluate Adherence Implementation Rates in Community Pharmacy (2019) · cites this paper as Pousinho et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Kirk, J. M. W., MacDonald, A., Lavender, P., Dean, J. M., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,902
Opportunities and responsibilities in pharmaceutical care
Hepler, C. D., & Strand, L. M. (1990) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/47.3.533 · Cited by 2,904
Turner, R. D., & Holman, R. R. (1998) · Cited by 1,974
Patient adherence to treatment: three decades of research. A comprehensive review
Vermeire, E., Hearnshaw, H., Royen, P. V., & Denekens, J. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00363.x · Cited by 1,833
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention
Wu, Y., Ding, Y., Tanaka, Y., & Zhang, W. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.10001 · Cited by 1,420
Wood, D., Backer, G. D., Færgeman, O., Graham, I. D., Mancia, G., & Pyörälà, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,253
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084
Barriers to diabetes management: patient and provider factors
Nam, S., Chesla, C., Stotts, N. A., Kroon, L., & Janson, S. L. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.02.002 · Cited by 680
Health-related quality of life in diabetes: The associations of complications with EQ-5D scores
Solli, O., Stavem, K., & Kristiansen, I. (2010) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-8-18 · Cited by 405
Evaluation of a Pharmaceutical Care Model on Diabetes Management
Jaber, L. A., Halapy, H., Fernet, M., Tummalapalli, S., & Diwakaran, H. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603000305 · Cited by 314
Correlates of health-related quality of life in type 2 diabetes
Wexler, D. J., Grant, R. W., Wittenberg, E., Bosch, J., Cagliero, E., Delahanty, L. M., Blais, M. A., & Meigs, J. B. (2006) · Diabetologia · doi:10.1007/s00125-006-0249-9 · Cited by 307
Patient Perceptions of Quality of Life With Diabetes-Related Complications and Treatments
Huang, E. S., Brown, S. E. S., Ewigman, B., Foley, E. C., & Meltzer, D. O. (2007) · Diabetes Care · doi:10.2337/dc07-0499 · Cited by 288
Effects of Pharmacist Outpatient Interventions on Adults with Diabetes Mellitus: A Systematic Review
Wubben, D. P., & Vivian, E. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.4.421 · Cited by 281
Rothman, R. L., Malone, R., Shilliday, B. B., Shintani, A., Crigler, B., DeWalt, D. A., Dittus, R. S., Weinberger, M., & Pignone, M. P. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.09.017 · Cited by 269
Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research.
Kozma, C. M., Reeder, C. E., & Schulz, R. (1993) · PubMed · Cited by 220
Choe, H. M., Mitrovich, S., Dubay, D., Hayward, R. A., Krein, S. L., & Vijan, S. S. (2005) · PubMed · Cited by 215
Effect of a Pharmaceutical Care Program on Vascular Risk Factors in Type 2 Diabetes
Clifford, R. M., Davis, W. A., Batty, K. T., & Davis, T. M. E. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.771 · Cited by 192
Krass, I., Armour, C. L., Mitchell, B., Brillant, M., Dienaar, R., Hughes, J., Lau, P. M.-Y., Peterson, G. M., Stewart, K., Taylor, S. E., et al. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02143.x · Cited by 188
Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus
Mazrouei, N. A., Kamal, M. M., Ghabash, N. M., Yacout, T. A., Kole, P. L., & McElnay, J. C. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03391.x · Cited by 178
Jarab, A. S., Alqudah, S., Mukattash, T. L., Shattat, G. F., & Al‐Qirim, T. M. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.7.516 · Cited by 170
Improving Care Transitions: Current Practice and Future Opportunities for Pharmacists
Hume, A. L., Kirwin, J. L., Bieber, H. L., Couchenour, R. L., Hall, D. L., Kennedy, A. K., LaPointe, N. M. A., Burkhardt, C. D., Schilli, K., Seaton, T., et al. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1215 · Cited by 168
Cohen, L. B., Taveira, T. H., Khatana, S. A. M., Dooley, A. G., Pirraglia, P. A., & Wu, W. (2011) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721711423980 · Cited by 153
Pharmacist Interventions to Improve Cardiovascular Disease Risk Factors in Diabetes
Santschi, V., Chiolero, A., Paradis, G., Colosimo, A. L., & Burnand, B. (2012) · Diabetes Care · doi:10.2337/dc12-0369 · Cited by 145 · cited 2×
“Regarding blood pressure, the systematic review conducted by Santschi et al. (2012) revealed that in comparison with the control group, 7 out of 12 (58.3”
BackgroundInfluentialOutcomes of pharmacist-managed diabetes care services in a community health center
Scott, D. M., Boyd, S. T., Stephan, M., Augustine, S. C., & Reardon, T. P. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060040 · Cited by 141
Mehuys, E., Van Bortel, L., De Bolle, L., Van Tongelen, I., Annemans, L., Remon, J.-P., & Giri, M. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01218.x · Cited by 139
The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996–2003
Eliasson, B., Cederholm, J., Nilsson, P. M., & Guðbjörnsdóttir, S. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01648.x · Cited by 128
Ali, M., Schifano, F., Robinson, P., Phillips, G., Doherty, L., Melnick, P., Laming, L., Sinclair, A. J., & Dhillon, S. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03725.x · Cited by 127
Caring for Poorly Controlled Diabetes Mellitus: A Randomized Pharmacist Intervention
Odegard, P. S., Goo, A., Hummel, J., Williams, K. L., & Gray, S. L. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e438 · Cited by 126
Fornos, J. A., de Andrés, N. F., Andrés, J. C., Guerra, M., & Egea, B. (2006) · Pharmacy World & Science · doi:10.1007/s11096-006-9003-0 · Cited by 124
Simpson, S. H., Majumdar, S. R., Tsuyuki, R. T., Lewanczuk, R. Z., Spooner, R., & Johnson, J. A. (2010) · Diabetes Care · doi:10.2337/dc10-1294 · Cited by 124
Malathy, R., Narmadha, M., Ramesh, S., Alvin, J. M., & Dinesh, B. (2011) · Journal of Young Pharmacists · doi:10.4103/0975-1483.76422 · Cited by 122
Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial
Mourão, A. D. O. M., Ferreira, W. R., Martins, M. A. P., Reis, A. M. M., Carrillo, M. R. G. G., Grabe‐Guimarães, A., & Ev, L. D. S. (2012) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-012-9710-7 · Cited by 114
Experience-based group education in Type 2 diabetes
Sarkadi, A., & Rosenqvist, U. (2004) · Patient Education and Counseling · doi:10.1016/j.pec.2003.10.009 · Cited by 109
Validity of Medication Adherence Self-Reports in Adults With Type 2 Diabetes
Gonzalez, J. S., Schneider, H. E., Wexler, D. J., Psaros, C., Delahanty, L. M., Cagliero, E., & Safren, S. A. (2012) · Diabetes Care · doi:10.2337/dc12-0410 · Cited by 106
Glucose, Lipid, and Blood Pressure Control in Australian Adults With Type 2 Diabetes
Kemp, T., Barr, E., Zimmet, P., Cameron, A. J., Welborn, T. A., Colagiuri, S., Phillips, P., & Shaw, J. E. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1490 · Cited by 101
Farsaei, S., Sabzghabaee, A. M., Zargarzadeh, A. H., & Amini, M. (2011) · PubMed Central · Cited by 98
Pharmacist-Led Group Medical Appointment Model in Type 2 Diabetes
Taveira, T. H., Friedmann, P. D., Cohen, L. B., Dooley, A. G., Khatana, S. A. M., Pirraglia, P. A., & Wu, W. (2009) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721709352383 · Cited by 97
Wishah, R. A., Al-Khawaldeh, O. A., & Albsoul-Younes, A. M. (2014) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2014.09.001 · Cited by 93
Improving Adherence and Reducing Medication Discrepancies in Patients with Diabetes
Grant, R. W., Devita, N. G., Singer, D. E., & Meigs, J. B. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c452 · Cited by 91
Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study
Jacobs, M. L., Sherry, P. S., Taylor, L. M., Amato, M. G., Tataronis, G. R., & Cushing, G. W. (2012) · Journal of the American Pharmacists Association · doi:10.1331/japha.2012.10183 · Cited by 84
Antoine, S., Pieper, D., Mathes, T., & Eikermann, M. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-53 · Cited by 82
Taveira, T. H., Dooley, A. G., Cohen, L. B., Khatana, S. A. M., & Wu, W. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q212 · Cited by 74
Chan, C.-W., Siu, S., Wong, C. K. W., & Lee, V. W. Y. (2011) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248410396216 · Cited by 74
Charpentier, G., Genès, N., Vaur, L., Amar, J., Clerson, P., Cambou, J., & Guéret, P. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70022-8 · Cited by 71
Chua, S. S., Chung, W. W., Lai, P. S. M., & Chan, S. P. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s66619 · Cited by 69
Suppapitiporn, S., Chindavijak, B., & Onsanit, S. (2005) · PubMed · Cited by 62
Nagavi, B., Adepu, R., & Rasheed, A. (2007) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.36937 · Cited by 62
Impact of pharmaceutical care on quality of life in patients with type 2 diabetes mellitus.
Sriram, S., Chack, L. E., Ramasamy, R., Ghasemi, A., Ravi, T. K., & Sabzghabaee, A. M. (2011) · Europe PMC (PubMed Central) · Cited by 56
Simpson, S. H., Lier, D. A., Majumdar, S. R., Tsuyuki, R. T., Lewanczuk, R. Z., Spooner, R., & Johnson, J. A. (2015) · Diabetic Medicine · doi:10.1111/dme.12692 · Cited by 54
Omran, D., Guirguis, L. M., & Simpson, S. H. (2012) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2012.07.002 · Cited by 52
Kjeldsen, L. J., Bjerrum, L., Dam, P., Larsen, B. O., Rossing, C., Søndergaard, B., & Herborg, H. (2014) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2014.03.003 · Cited by 44
Health-related quality of life measurement in pharmaceutical care Targeting an outcome that matters
Kheir, N. M., van Mil, J. W. F., Shaw, J., & Sheridan, J. L. (2004) · Pharmacy World & Science · doi:10.1023/b:phar.0000026811.37414.4f · Cited by 38
Role of community pharmacists in improving knowledge and glycemic control of type 2 diabetes
Venkatesan, R., Devi, A. M., Parasuraman, S., & Sriram, S. (2012) · Perspectives in Clinical Research · doi:10.4103/2229-3485.92304 · Cited by 36
Adibe, M. O., Ukwe, C. V., & Aguwa, C. N. (2013) · Value in Health Regional Issues · doi:10.1016/j.vhri.2013.06.007 · Cited by 35
Adibe, M. O., Aguwa, C. N., & Ukwe, C. V. (2013) · Value in Health Regional Issues · doi:10.1016/j.vhri.2013.06.009 · Cited by 35
Plaster, C. P., Melo, D. T., Boldt, V., Cassaro, K. O. D. S., Lessa, F. C. R., Boëchat, G. A. P., Bissoli, N. S., & de Andrade, T. U. (2012) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502012000300010 · Cited by 33
Is adherence a relevant issue in the self-management education of diabetes? A mixed narrative review
Debussche, X. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s36369 · Cited by 27
Strategies for Pharmacists in the Implementation of Diabetes Mellitus Management Programs
Nichols-English, G. J., Provost, M., Koompalum, D., Chen, H., & Masood, A. (2002) · Disease Management & Health Outcomes · doi:10.2165/00115677-200210120-00005 · Cited by 19
Rodríguez, N. F. A., Pérez, J. A. F., & Iglesias, J. C. A. (2007) · Pharmaceutical care España · Cited by 6
Ghosh, S., Rajvanshi, A. K., & Kishun, S. (2010) · International Journal of Pharma and Bio Sciences · Cited by 5
Research works printed but not linked: 14
- International Diabetes Federation, 2015, IDF Diabetes Atlas
- Hepler CD, 1990, Am J Hosp Pharm, 47, 533
- Choe HM, 2005, Am J Manag Care, 11, 253
- Adepu R, 2010, Asian J Pharm Clin Res, 3, 174
- Chung WW, 2014, Patient Prefer Adherence, 8, 1185
- Farsaei S, 2011, J Res Med Sci, 16, 43
- Ghosh S, 2010, Int J Pharma Bio Sci, 1, 1
- Mahwi TO, 2013, Int J Pharm Sci Res, 4, 1363
- Ramanath KV, 2011, Asian J Pharm Clin Res, 4, 15
- Sriram S, 2011, J Res Med Sci, 16, S412
- Suppapitiporn S, 2005, J Med Assoc Thai, 88, S134
- 10.1042/cs1010671 · DOI · Paper page
- Rodríguez NFA, 2007, Pharm Care Esp, 9, 2
- Kozma CM, 1993, Clin Ther, 15, 1121
Cited by
Sorted by citations
Cardiovascular disease as a leading cause of death: how are pharmacists getting involved?
Namara, K. M., Alzubaidi, H., & Jackson, J. K. (2019) · Integrated Pharmacy Research and Practice · doi:10.2147/iprp.s133088 · Cited by 414
Presley, B., Groot, W. N. J., & Pavlova, M. (2018) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2018.09.021 · Cited by 178
OECD (2021) · OECD Reviews of Health Systems · doi:10.1787/120e170e-en · Cited by 171
Newman, T. V., San-Juan-Rodriguez, A., Parekh, N., Swart, E. C. S., Klein‐Fedyshin, M., Shrank, W. H., & Hernandez, I. (2020) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2019.12.016 · Cited by 158
van Eikenhorst, L., Taxis, K., van Dijk, L., & de Gier, H. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00891 · Cited by 121
Metadata
- Authors
- Pousinho, S., Morgado, M., Falcão, A., & Alves, G.
- Affiliations
- University of Beira Interior (PT)
- Centro de Neurociências e Biologia Celular (PT)
- Venue
- Journal of Managed Care & Specialty Pharmacy
- Publisher
- Academy of Managed Care Pharmacy
- Published
- 2016-05
- Volume
- 22
- Issue
- 5
- Pages
- 493-515
- ISSN
- 2376-0540 (ISSN-L)
- 2376-1032
- PMC
- PMC10397609
- OpenAlex
- W2345232808
- Cited by
- 199
- References
- 79
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 13 · 2023: 17 · 2022: 31 · 2021: 31 · 2020: 28 · 2019: 21 · 2018: 13 · 2017: 20 · 2016: 2
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Managed Care & Specialty Pharmacy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Universidade da Beira Interior
- Universidade de Coimbra
- Topics
- Health Sciences › Health Professions › Pharmacy › Pharmacy and Medical Practices
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacist intervention, type 2 diabetes, HbA1c, blood pressure, lipid profile, LDL cholesterol, total cholesterol, body mass index, medication adherence, health-related quality of life, coronary heart disease risk, economic outcomes, community pharmacy, primary care, hospital pharmacy, integrated care teams, diabetes management, usual care comparison, risk of bias, heterogeneity of results, publication bias
- MeSH terms
- Aged, Blood Pressure, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Pharmacists, Quality of Life, Randomized Controlled Trials as Topic, Disease Management, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
